GlassScriptPhysician profile
Ebenezer Aluma
NPI 1649668427
$1,189.35
in general payments reported to CMS, 2019-2025
13 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $66.48 · 2023: $381 · 2024: $511 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.41 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $282.16 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $230.52 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Indivior INC. | $91.19 | 2024-2025 | Sublocade |
| Axsome Therapeutics, INC. | $47.75 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $30.23 | 2023 | Quviviq |
| Gilead Sciences, INC. | $26.08 | 2024 | |
| Corium, LLC | $24.25 | 2024 | Azstarys |
| Braeburn INC. | $21.94 | 2025 | Brixadi |
| Lundbeck LLC | $19.56 | 2025 | Rexulti |
| Tris Pharma INC | $16.87 | 2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $14.33 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebenezer Aluma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.